Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;21(2):196-203.
doi: 10.1038/s41391-018-0045-x. Epub 2018 May 23.

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer

Emma H Allott  1 , Elizabeth M Masko  2 , Alexis R Freedland  3 , Everardo Macias  3 , Kristine Pelton  4 , Keith R Solomon  5   6 , Elahe A Mostaghel  7   8 , George V Thomas  9   10 , Salvatore V Pizzo  11 , Michael R Freeman  3 , Stephen J Freedland  12   13
Affiliations

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer

Emma H Allott et al. Prostate Cancer Prostatic Dis. 2018 Jun.

Abstract

Background: Some, but not all, epidemiologic evidence supports a role for cholesterol, the precursor for steroid hormone synthesis, in prostate cancer. Using a PTEN-null transgenic mouse model of prostate cancer, we tested the effect of modifying serum cholesterol levels on prostate tumor development and growth. We hypothesized that serum cholesterol reduction would lower tumor androgens and slow prostate cancer growth.

Methods: PTENloxP/loxP-Cre+ mice consuming ad libitum high fat, high cholesterol diets (40% fat, 1.25% cholesterol) were randomized after weaning to receive the cholesterol uptake inhibitor, ezetimibe (30 mg/kg/day), or no intervention, and sacrificed at 2, 3, or 4 months of age. Serum cholesterol and testosterone were measured by ELISA and intraprostatic androgens by mass spectrometry. Prostate histology was graded, and proliferation and apoptosis in tumor epithelium and stroma was assessed by Ki67 and TUNEL, respectively.

Results: Ezetimibe-treated mice had lower serum cholesterol at 4 months (p = 0.031). Serum cholesterol was positively correlated with prostate weight (p = 0.033) and tumor epithelial proliferation (p = 0.069), and negatively correlated with tumor epithelial apoptosis (p = 0.004). Serum cholesterol was unrelated to body weight (p = 0.195). Tumor stromal cell proliferation was reduced in the ezetimibe group (p = 0.010). Increased serum cholesterol at 4 months was associated with elevated intraprostatic DHEA, testosterone, and androstenedione (p = 0.043, p = 0.074, p = 0.031, respectively). However, cholesterol reduction did not significantly affect adenocarcinoma development at 2, 3, or 4 months of age (0, 78, and 100% in ezetimibe-treated vs. 0, 80, and 100% in mice not receiving ezetimibe).

Conclusions: Though serum cholesterol reduction did not significantly affect the rate of adenocarcinoma development in the PTEN-null transgenic mouse model of prostate cancer, it lowered intraprostatic androgens and slowed tumor growth. These findings support a role for serum cholesterol in promoting prostate cancer growth, potentially via enhanced tumor androgen signaling, and may provide new insight into cholesterol-lowering interventions for prostate cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Caloric intake (A) and body weight (B) trajectories throughout the study duration in the PTEN-null transgenic mouse model of prostate cancer, median differences in serum cholesterol level between dietary groups at 4 months of age (C), and correlation between body weight at 4 months of age and serum cholesterol levels (D).
Figure 2
Figure 2
Effect of serum cholesterol reduction on prostate weight at 4 months of age in the PTEN-null transgenic mouse model
Figure 3
Figure 3
Effect of cholesterol reduction on proliferation and apoptosis in prostate tumor epithelium at 4 months of age in the PTEN-null transgenic mouse model
See this image and copyright information in PMC

References

    1. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. European urology. 2013;63(5):800–809. - PMC - PubMed
    1. Fryar CD, Chen TC, Li X. Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999–2010. NCHS data brief. 2012;(103):1–8. - PubMed
    1. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2807–2813. - PMC - PubMed
    1. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer causes & control : CCC. 2011;22(11):1545–1552. - PMC - PubMed
    1. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up. BMC cancer. 2012;12:25. - PMC - PubMed